{"nct_id":"NCT06710288","title":"A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer","status":"RECRUITING","status_verified_date":"2025-07","start_date":"2024-11-06","start_date_type":"ACTUAL","primary_completion_date":"2027-05","primary_completion_date_type":"ESTIMATED","completion_date":"2027-05","completion_date_type":"ESTIMATED","phases":["PHASE2"],"tickers":["IBRX"]}